CN106456751B - 治疗指甲和头皮银屑病的方法 - Google Patents

治疗指甲和头皮银屑病的方法 Download PDF

Info

Publication number
CN106456751B
CN106456751B CN201580017495.1A CN201580017495A CN106456751B CN 106456751 B CN106456751 B CN 106456751B CN 201580017495 A CN201580017495 A CN 201580017495A CN 106456751 B CN106456751 B CN 106456751B
Authority
CN
China
Prior art keywords
antibody
psoriasis
seq
patient
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580017495.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN106456751A (zh
Inventor
阿贾伊·尼鲁拉
中川秀己
大泷显司
松户泰树
保罗·克勒科特卡
格雷戈里·克里克里恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen K A Inc
Original Assignee
Amgen K A Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen K A Inc filed Critical Amgen K A Inc
Publication of CN106456751A publication Critical patent/CN106456751A/zh
Application granted granted Critical
Publication of CN106456751B publication Critical patent/CN106456751B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
CN201580017495.1A 2014-03-31 2015-03-19 治疗指甲和头皮银屑病的方法 Active CN106456751B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461972638P 2014-03-31 2014-03-31
US61/972,638 2014-03-31
US201462031850P 2014-07-31 2014-07-31
US62/031,850 2014-07-31
US201462041879P 2014-08-26 2014-08-26
US62/041,879 2014-08-26
PCT/US2015/021613 WO2015153144A1 (en) 2014-03-31 2015-03-19 Methods of treating nail and scalp psoriasis

Publications (2)

Publication Number Publication Date
CN106456751A CN106456751A (zh) 2017-02-22
CN106456751B true CN106456751B (zh) 2021-02-02

Family

ID=52808190

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580017495.1A Active CN106456751B (zh) 2014-03-31 2015-03-19 治疗指甲和头皮银屑病的方法

Country Status (11)

Country Link
US (1) US20170174772A1 (cg-RX-API-DMAC7.html)
EP (1) EP3126392B1 (cg-RX-API-DMAC7.html)
JP (1) JP6596014B2 (cg-RX-API-DMAC7.html)
KR (2) KR102530900B1 (cg-RX-API-DMAC7.html)
CN (1) CN106456751B (cg-RX-API-DMAC7.html)
AU (1) AU2015241373B2 (cg-RX-API-DMAC7.html)
CA (1) CA2944605C (cg-RX-API-DMAC7.html)
ES (1) ES2760002T3 (cg-RX-API-DMAC7.html)
MY (1) MY184189A (cg-RX-API-DMAC7.html)
SG (1) SG11201607881SA (cg-RX-API-DMAC7.html)
WO (1) WO2015153144A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
PT3295957T (pt) 2010-01-15 2019-11-12 Kirin Amgen Inc Formulação de anticorpo anti il-17ra e regimes terapêuticos para o tratamento de psoríase
CN105534996B (zh) * 2016-02-24 2018-05-01 长沙佰顺生物科技有限公司 一种治疗银屑病的药物组合物
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
JP7033774B2 (ja) * 2017-08-25 2022-03-11 国立大学法人 東京大学 抗サイトカイン抗体療法
CN111670036B (zh) * 2018-01-31 2024-08-09 安成生物科技股份有限公司 包含托法替尼的局部调配物
US12161748B2 (en) 2018-01-31 2024-12-10 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
CA3091598A1 (en) 2018-02-22 2019-08-29 Tokai University Educational System Il-17a activity inhibitor and use thereof
JOP20210229A1 (ar) 2019-02-18 2023-01-30 Lilly Co Eli صيغة جسم مضاد علاجي
JP2022547678A (ja) * 2019-09-11 2022-11-15 ボシュ ヘルス アイルランド リミテッド Ｉｌ－１７ｒａ抗体を用いた非アルコール性脂肪性肝疾患（ｎａｆｌｄ）の治療方法
CN114423455A (zh) * 2019-09-25 2022-04-29 国立大学法人东京大学 用于治疗系统性硬化症的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101541833A (zh) * 2006-10-02 2009-09-23 安姆根有限公司 Il-17受体a抗原结合蛋白质
CN102821787A (zh) * 2010-01-15 2012-12-12 麒麟-安姆根有限公司 抗体制剂和治疗方案

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE59010941D1 (de) 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
EP0398327B2 (en) 1989-05-18 2013-02-20 Yeda Research And Development Co., Ltd. Tumor necrosis factor binding protein II, its purification and antibodies thereto
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
CA2065346C (en) 1989-09-05 2005-03-29 Craig A. Smith Tumor necrosis factor-.alpha. and-.beta. receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
JPH03127800A (ja) 1989-10-13 1991-05-30 Teijin Ltd 腫瘍壊死因子活性抑制物質
JPH0578396A (ja) 1989-12-13 1993-03-30 Yeda Res & Dev Co Ltd ヒト腫瘍壊死因子結合蛋白
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
ATE169030T1 (de) 1990-06-28 1998-08-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
WO1992013095A1 (en) 1991-01-18 1992-08-06 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases
SG89295A1 (en) 1991-03-15 2002-06-18 Amgen Inc Pegylation of polypeptides
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993007863A1 (en) 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
EP1239043A3 (en) 1992-03-30 2003-01-02 Immunex Corporation Fusion proteins comprising tumour necrosis factor receptor
JPH07509223A (ja) 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
JPH05312248A (ja) 1992-05-08 1993-11-22 Nissan Motor Co Ltd シフトレバー装置
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5869286A (en) 1995-03-23 1999-02-09 Immunex Corporation Receptor that binds IL-17
US7030565B2 (en) 2004-07-27 2006-04-18 Jerrell Penn Hollaway Lamp control circuit with selectable color signals
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JP5537740B2 (ja) * 2010-10-08 2014-07-02 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法
US9413463B2 (en) 2013-08-30 2016-08-09 Google Inc. Apparatus and method for efficient two-way optical communication where transmitter may interfere with receiver
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101541833A (zh) * 2006-10-02 2009-09-23 安姆根有限公司 Il-17受体a抗原结合蛋白质
CN102821787A (zh) * 2010-01-15 2012-12-12 麒麟-安姆根有限公司 抗体制剂和治疗方案

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Psoriasis;Jashin J. Wu, M.D.等;《T h e new engl and journa l o f medicine》;20120329;第366卷(第13期);274-275 *
Brodalumab, an Anti–Interleukin-17–Receptor Antibodyfor Psoriasis;Kim A. Papp, M.D.,等;《T h e new engl and journa l o f medicine》;20120329;第366卷(第13期);1181-1189 *
Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation;C. Stanley Chan等;《J AM ACAD DERMATOL》;20090420;第60卷(第6期);962-971 *
英夫利昔单抗诱导和维持治疗中重度银屑病的三期临床多中心双盲对照试验;reich k等;《世界核心医学期刊文摘 皮肤病学》;20060131;第2卷(第1期);1 *

Also Published As

Publication number Publication date
CN106456751A (zh) 2017-02-22
US20170174772A1 (en) 2017-06-22
EP3126392B1 (en) 2019-09-11
WO2015153144A1 (en) 2015-10-08
KR102530900B1 (ko) 2023-05-12
EP3126392A1 (en) 2017-02-08
JP6596014B2 (ja) 2019-10-23
ES2760002T3 (es) 2020-05-12
CA2944605A1 (en) 2015-10-08
AU2015241373B2 (en) 2020-11-05
JP2017511316A (ja) 2017-04-20
MY184189A (en) 2021-03-24
KR20220093008A (ko) 2022-07-04
SG11201607881SA (en) 2016-10-28
AU2015241373A1 (en) 2016-10-06
CA2944605C (en) 2023-10-17
KR20160130248A (ko) 2016-11-10

Similar Documents

Publication Publication Date Title
CN106456751B (zh) 治疗指甲和头皮银屑病的方法
RU2707745C2 (ru) Способы лечения или профилактики мигренозной головной боли
DK2699598T3 (en) COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
KR102576903B1 (ko) Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
CN118924895A (zh) 用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案
CN104755495A (zh) 通过施用il-4r拮抗剂治疗或预防哮喘的方法
US10968278B2 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
JP2021193121A (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
KR20220158821A (ko) Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
WO2019173523A1 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
JP2022126791A (ja) Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
EP3873533A1 (en) Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate
JP2020100630A (ja) オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法
KR20250096792A (ko) Il-4r 길항제를 투여하여 손 및 발 피부염을 치료하기 위한 방법
RU2845158C1 (ru) Способы лечения атопического дерматита путем введения антагониста il-4r
TW202535463A (zh) Ａｎｃａ相關血管炎之治療
TW202400228A (zh) 減輕細胞激素釋放症候群的給藥方案
WO2025096435A1 (en) Treatment of complement-associated renal diseases
HK40057787A (en) Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate
EA048671B1 (ru) Конъюгаты антител к тканевому фактору с лекарственными средствами и их применение при лечении рака

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: American California

Applicant after: Amgen K-A Co., Ltd.

Address before: American California

Applicant before: Kirin Amgen Inc

GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: California, USA

Patentee after: Amgen K-a Co.

Address before: California, USA

Patentee before: Amgen K-A Co.,Ltd.